The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0530 GMT - Terumo's exit from its plasma collection business is likely to drag sales in the near term but strengthen its longer-term earnings, Jefferies analysts say in a note. As a result of the exit, the Japanese medical equipment maker is taking a $610 million charge and cutting fiscal-year earnings guidance. The U.S. bank cuts its Terumo revenue forecast for the fiscal year starting in April 2027 but raises operating profit estimates for the period onward. The bank says Terumo management expects profitability for blood and cell technologies to improve, as resources are redirected toward higher-growth, higher-margin apheresis and blood processing franchises. Jefferies cuts its target price to 2,700 yen from Y3,300 and keeps its buy rating. Shares are 2.0% lower at Y2,261.5. (kosaku.narioka@wsj.com; @kosakunarioka)

1208 GMT - GSK CEO Luke Miels sees the U.K. drugmaker's oncology business as underappreciated by the market and expects upcoming updates at a medical congress to boost investors' confidence, J.P. Morgan analysts say, citing a recent call with Miels. "[Miels] reiterated his confidence in delivering GSK's 2031 sales target of [more than 40 billion pounds], pointing to the breadth and depth of the portfolio, particularly in oncology, which [Miels] sees as underappreciated by consensus," the analysts say in a note. GSK expects to provide updates on its oncology portfolio at the annual congress of the European Society For Medical Oncology, which Miels expects will improve confidence in the pipeline, JPM says. Shares fall 1.8%. (adria.calatayud@wsj.com)

1158 GMT - The latest study results from an obesity drug candidate that Roche Holding and Zealand Pharma are jointly developing seem unlikely to alter investors' views on the product, Jefferies analysts say in a research note. The drug, petrelintide, showed a modest effect in reducing blood-sugar levels and the reported weight-loss rate of 9.2% in obese patients with type 2 diabetes was broadly as expected, according to Jefferies. This suggests petrelintide's weight-loss efficacy fell by between 15% and 20% for this group compared with nondiabetic obesity patients, for whom Zealand previously reported a 10.7% reduction, the analysts say. A benign tolerability profile remains the main point of differentiation for the drug, the analysts say. Zealand Pharma shares fall 4%, while Roche's trade 1.4% lower. (adria.calatayud@wsj.com)

1140 GMT - Argenx's positive results for a midstage clinical trial in celiac disease vindicates its CEO change earlier this year, Bernstein analysts say in a research note. The Amsterdam-based biotech company said a drug candidate it acquired through its Forte Biosciences deal, FB102, hit the goal in a study, reinforcing the potential of a medicine being tested for two diseases with little or no existing nonsystemic drug treatment options, the analysts say. "A key rationale for the CEO transition was to diversify the organic pipeline with external innovation," the analysts add. Argenx separately said it would discontinue a trial for its main drug Vyvgart in Sjogren's disease. This should come as little surprise given that Sjogren's is a heterogeneous disease that has become a research-and-development "graveyard" for the industry, according to Bernstein. Shares fall 16%. (adria.calatayud@wsj.com)

1125 GMT - Argenx's decision to stop a late-stage clinical trial of its Vyvgart drug in Sjogren's disease comes as a major negative surprise for the European biotech company, UBS analysts say in a note. "We believe Argenx's discontinuation of Sjogren's study at interim suggests potentially very little efficacy--if any--not just a 'near miss'," the analysts say. The drug had generated positive and solid results in a midstage study, as had a similar medicine from rival Johnson & Johnson, Imaavy, they add. The study was supposed to be one of the most closely watched updates from Argenx next year, and UBS had modeled peak annual sales for Vyvgart in Sjogren's at $3.5 billion, the analysts say. Shares fall 16%.